TFX Quote, Financials, Valuation and Earnings

Elutia, Inc. has a net margin of -44.78% compared to Teleflex, Inc.'s net margin of -11.53%. Teleflex, Inc.'s return on equity of -7.84% beat Elutia, Inc.'s return on equity of --.

Teleflex, Inc. has a consensus price target of $124.14, signalling downside risk potential of -5.42%. On the other hand Elutia, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 468.18%. Given that Elutia, Inc. has higher upside potential than Teleflex, Inc., analysts believe Elutia, Inc. is more attractive than Teleflex, Inc..

Teleflex, Inc. has a beta of 0.954, which suggesting that the stock is 4.59% less volatile than S&P 500. In comparison Elutia, Inc. has a beta of 0.630, suggesting its less volatile than the S&P 500 by 37.049%.

Teleflex, Inc. has a quarterly dividend of $0.34 per share corresponding to a yield of 1.04%. Elutia, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex, Inc. pays 91.92% of its earnings as a dividend. Elutia, Inc. pays out -- of its earnings as a dividend. Teleflex, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex, Inc. quarterly revenues are $913M, which are larger than Elutia, Inc. quarterly revenues of $3.3M. Teleflex, Inc.'s net income of -$408.9M is lower than Elutia, Inc.'s net income of -$383K. Notably, Teleflex, Inc.'s price-to-earnings ratio is 25.75x while Elutia, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex, Inc. is 1.86x versus 1.43x for Elutia, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of -44.78% compared to Teleflex, Inc.'s net margin of 15.47%. Teleflex, Inc.'s return on equity of -7.84% beat Globus Medical, Inc.'s return on equity of 10.08%.

Teleflex, Inc. has a consensus price target of $124.14, signalling downside risk potential of -5.42%. On the other hand Globus Medical, Inc. has an analysts' consensus of $95.70 which suggests that it could grow by 8.23%. Given that Globus Medical, Inc. has higher upside potential than Teleflex, Inc., analysts believe Globus Medical, Inc. is more attractive than Teleflex, Inc..

Teleflex, Inc. has a beta of 0.954, which suggesting that the stock is 4.59% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.070, suggesting its more volatile than the S&P 500 by 7.046%.

Teleflex, Inc. has a quarterly dividend of $0.34 per share corresponding to a yield of 1.04%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex, Inc. pays 91.92% of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend. Teleflex, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex, Inc. quarterly revenues are $913M, which are larger than Globus Medical, Inc. quarterly revenues of $769M. Teleflex, Inc.'s net income of -$408.9M is lower than Globus Medical, Inc.'s net income of $119M. Notably, Teleflex, Inc.'s price-to-earnings ratio is 25.75x while Globus Medical, Inc.'s PE ratio is 28.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex, Inc. is 1.86x versus 4.40x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Repligen Corp. has a net margin of -44.78% compared to Teleflex, Inc.'s net margin of 7.9%. Teleflex, Inc.'s return on equity of -7.84% beat Repligen Corp.'s return on equity of 0.09%.

Teleflex, Inc. has a consensus price target of $124.14, signalling downside risk potential of -5.42%. On the other hand Repligen Corp. has an analysts' consensus of $187.56 which suggests that it could grow by 16.73%. Given that Repligen Corp. has higher upside potential than Teleflex, Inc., analysts believe Repligen Corp. is more attractive than Teleflex, Inc..

Teleflex, Inc. has a beta of 0.954, which suggesting that the stock is 4.59% less volatile than S&P 500. In comparison Repligen Corp. has a beta of 1.110, suggesting its more volatile than the S&P 500 by 11.028%.

Teleflex, Inc. has a quarterly dividend of $0.34 per share corresponding to a yield of 1.04%. Repligen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex, Inc. pays 91.92% of its earnings as a dividend. Repligen Corp. pays out -- of its earnings as a dividend. Teleflex, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex, Inc. quarterly revenues are $913M, which are larger than Repligen Corp. quarterly revenues of $188.8M. Teleflex, Inc.'s net income of -$408.9M is lower than Repligen Corp.'s net income of $14.9M. Notably, Teleflex, Inc.'s price-to-earnings ratio is 25.75x while Repligen Corp.'s PE ratio is 6,227.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex, Inc. is 1.86x versus 12.80x for Repligen Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care, Inc. has a net margin of -44.78% compared to Teleflex, Inc.'s net margin of -8.49%. Teleflex, Inc.'s return on equity of -7.84% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.

Teleflex, Inc. has a consensus price target of $124.14, signalling downside risk potential of -5.42%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $22.52 which suggests that it could grow by 10.2%. Given that Tandem Diabetes Care, Inc. has higher upside potential than Teleflex, Inc., analysts believe Tandem Diabetes Care, Inc. is more attractive than Teleflex, Inc..

Teleflex, Inc. has a beta of 0.954, which suggesting that the stock is 4.59% less volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.685, suggesting its more volatile than the S&P 500 by 68.536%.

Teleflex, Inc. has a quarterly dividend of $0.34 per share corresponding to a yield of 1.04%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex, Inc. pays 91.92% of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend. Teleflex, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex, Inc. quarterly revenues are $913M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Teleflex, Inc.'s net income of -$408.9M is lower than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Teleflex, Inc.'s price-to-earnings ratio is 25.75x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex, Inc. is 1.86x versus 1.36x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.